Li Tao, Liang Hongyan, Yan Feng, Lu Shengdong
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.
Zhonghua Yi Xue Za Zhi. 2002 Oct 10;82(19):1324-7.
To prolong the half-life and enhance the biological activity of the human atrial natriuretic peptide (hANP), a peptide hormone, which is synthesized and released mainly by cardiac atrial myocytes and possesses potent natriuretic, diretic, and vasorelaxant properties.
The site-directed mutation technique based on polymerase chain reaction was performed to get the mutant of the human ANP gene (mhANP), and the retroviral expression vector, pLHY24, in which mhANP gene is under the transcriptional control of the human cytomegalovirus promoter, was constructed. The naked plasmid DNA of pLHY24 and positive control vector, pLHY19, in which the wild-type hNAP gene is in the same conditions as mhANP gene in pLHY24, and negative control vector, pLNCX without purpose gene, at a dose of 5 mg/kg body weight was injected intramuscularly into the rats with experimental renal disorder induced with adriamycin (ADR), respectively.
DNA sequencing result proved that the respected mhANP gene with the point mutations of TTC(131)/Phe-->TCC/Ser and ATG(135)/Met-->ATA/Ile has been obtained. In comparison with negative control group (87 +/- 7.1 pg/ml), a single intramuscular injection of expression vector harboring mhANP or hANP gene resulted in an obvious increase in plasma level of mhANP (107 +/- 7.8 pg/ml, t = 4.65, P < 0.01) or hANP (113 +/- 8.6 pg/ml, t = 5.71, P < 0.01) 5 days after injection. A significant elevation in the ratio of urine volume to body weight was occurred after both of mhANP gene and hANP gene delivery as compared with negative control and the effect lasted for more than 15 days. The diuretic activity of mhANP gene delivery was 1.6-, 2.0-, and 1.9-fold higher than that of hANP gene 5, 10, and 15 days after gene transfer, respectively. However, there were no statistical differences in the concentrations of K(+) and Na(+) in urine.
Both of mhANP and hANP gene delivery into the rats with experimental nephropathy could improve their directic function obviously and the diuretic activity of the former is stronger than that of the latter significantly.
延长人心房利钠肽(hANP)的半衰期并增强其生物活性。hANP是一种肽类激素,主要由心房肌细胞合成并释放,具有强大的利钠、利尿和血管舒张特性。
采用基于聚合酶链反应的定点突变技术获得人ANP基因的突变体(mhANP),构建逆转录病毒表达载体pLHY24,其中mhANP基因受人类巨细胞病毒启动子的转录控制。将pLHY24的裸质粒DNA、阳性对照载体pLHY19(其中野生型hNAP基因与pLHY24中mhANP基因处于相同条件)和阴性对照载体pLNCX(无目的基因)分别以5mg/kg体重的剂量肌肉注射到用阿霉素(ADR)诱导的实验性肾脏疾病大鼠体内。
DNA测序结果证明已获得具有TTC(131)/Phe→TCC/Ser和ATG(135)/Met→ATA/Ile点突变的相应mhANP基因。与阴性对照组(87±7.1pg/ml)相比,单次肌肉注射携带mhANP或hANP基因的表达载体后,注射5天后血浆中mhANP(107±7.8pg/ml,t = 4.65,P < 0.01)或hANP(113±8.6pg/ml,t = 5.71,P < 0.01)水平明显升高。与阴性对照组相比,mhANP基因和hANP基因导入后,尿量与体重之比均显著升高,且该效应持续超过15天。基因转移后5、10和15天,mhANP基因导入的利尿活性分别比hANP基因高1.6倍、2.0倍和1.9倍。然而,尿中K(+)和Na(+)浓度无统计学差异。
将mhANP和hANP基因导入实验性肾病大鼠体内均可明显改善其利尿功能,且前者的利尿活性明显强于后者。